What is Amphastar Pharmaceuticals, Inc.'s Market Cap?

Amphastar Pharmaceuticals, Inc.'s Market Cap is $967.7M, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s Enterprise Value?

Amphastar Pharmaceuticals, Inc.'s Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s Trailing P/E?

Amphastar Pharmaceuticals, Inc.'s Trailing P/E is 12.3×, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s Price / Sales?

Amphastar Pharmaceuticals, Inc.'s Price / Sales is 1.3×, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s EV / Revenue?

Amphastar Pharmaceuticals, Inc.'s EV / Revenue is 1.8×, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s EV / EBITDA?

Amphastar Pharmaceuticals, Inc.'s EV / EBITDA is 7.6×, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s Revenue (TTM)?

Amphastar Pharmaceuticals, Inc.'s Revenue (TTM) is $730.0M, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s Net Income (TTM)?

Amphastar Pharmaceuticals, Inc.'s Net Income (TTM) is $78.5M, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s EBITDA?

Amphastar Pharmaceuticals, Inc.'s EBITDA is $171.4M, based on as-reported figures from SEC (XBRL) filings.

What is Amphastar Pharmaceuticals, Inc.'s Diluted EPS (TTM)?

Amphastar Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 1.85, based on as-reported figures from SEC (XBRL) filings.

Amphastar Pharmaceuticals, Inc. (AMPH) Financial Statements

Amphastar Pharmaceuticals, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001SCM4W2

XNAS · usd

22.75▼ 0.18 (-0.78%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close22.93

Day's Range22.30 – 23.14

52-Week Range16.65 – 29.53

Volume451.3K

Avg Volume414.2K

Share Statistics

Shares Outstanding

Employees1,976

ExchangeXNAS

Listed2014-06-25

Share count as of July 31, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Amphastar Pharmaceuticals, Inc. (AMPH)

What is Amphastar Pharmaceuticals, Inc.'s Market Cap?: Amphastar Pharmaceuticals, Inc.'s Market Cap is $967.7M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Enterprise Value?: Amphastar Pharmaceuticals, Inc.'s Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Trailing P/E?: Amphastar Pharmaceuticals, Inc.'s Trailing P/E is 12.3×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Price / Sales?: Amphastar Pharmaceuticals, Inc.'s Price / Sales is 1.3×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s EV / Revenue?: Amphastar Pharmaceuticals, Inc.'s EV / Revenue is 1.8×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s EV / EBITDA?: Amphastar Pharmaceuticals, Inc.'s EV / EBITDA is 7.6×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Revenue (TTM)?: Amphastar Pharmaceuticals, Inc.'s Revenue (TTM) is $730.0M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Net Income (TTM)?: Amphastar Pharmaceuticals, Inc.'s Net Income (TTM) is $78.5M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s EBITDA?: Amphastar Pharmaceuticals, Inc.'s EBITDA is $171.4M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Diluted EPS (TTM)?: Amphastar Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 1.85, based on as-reported figures from SEC (XBRL) filings.